“Pivotal nonclinical studies were conducted in Cynomolgus monkeys.”
✓ VerifiedFDA pharmacology/toxicology review, p. 2Source ↗
Why that species
Binds human and cynomolgus IL-5Rα with similar affinity (KD 11 and 42 pM); no cross-reactivity with murine IL-5Rα
“Benralizumab binds to human and cynomolgus monkey IL-5Rα with KD values of 11 and 42 pM, respectively (as measured by BIAcore). Benralizumab did not cross-react with murine IL-5Rα.”
✓ VerifiedFDA pharmacology/toxicology review, p. 38Source ↗
Surrogate molecule
No surrogate (mouse surrogate judged not required); the clinical antibody was tested in cynomolgus monkeys
“Further, the ECAC agreed that development of a mouse surrogate was not required.”
✓ VerifiedFDA pharmacology/toxicology review, p. 40Source ↗
Species: general tox
Cynomolgus monkey only (toxicology studies up to 39 weeks)
“Pivotal nonclinical studies were conducted in Cynomolgus monkeys. In toxicology studies up to 39 weeks duration, NOAELs of 10 mg/kg IV and 30 mg/kg SC were identified.”
✓ VerifiedFDA pharmacology/toxicology review, p. 2Source ↗
Species: DART
Cynomolgus monkey (enhanced pre- and postnatal development; fertility in 39-week study)
“An enhanced pre- and post-natal development studies were conducted with cynomolgus monkeys to evaluate benralizumab’s effects on development.”
✓ VerifiedFDA pharmacology/toxicology review, p. 2Source ↗
Species: carcinogenicity
Not conducted (rodents not pharmacologically relevant)
“Carcinogenicity studies were not conducted since rodents are not pharmacologically relevant species.”
✓ VerifiedFDA pharmacology/toxicology review, p. 2Source ↗
Surrogate used in
No surrogate used; ECAC agreed a mouse surrogate was not required
“Further, the ECAC agreed that development of a mouse surrogate was not required.”
✓ VerifiedFDA pharmacology/toxicology review, p. 40Source ↗